Technologies

StataDX licensed the eRapid portable electrochemical sensing technology to develop diagnostics for neurological, cardiovascular, and renal diseases with a first focus on building a point-of-care platform for difficult-to-detect neurological disorders.

Project 1985 is commercializing the Wyss Institute’s Pop-Up MEMS technology to quickly and cheaply develop tiny robotic tools for minimally invasive surgery.

Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.

Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized.

This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute.

Nearly 60% of greenhouse gas emissions are linked to the production and processing of meat. Using Wyss-developed technology, an alternative meat can be made from vegetable protein that has the same taste and texture as animal products.